FDA Determines Regulatory Review Period for ZILVER PTX Drug Eluting Peripheral Stent Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the ZILVER PTX Drug Eluting Peripheral Stent patent extension, as required by law, following a submission by Cook Medical Technologies, LLC to the U.S. Patent and Trademark Office (USPTO)